Why Should Curcumin BCM-95® Be Your Preferred Source of Curcumin?

Curcumin BCM-95®

- Enhanced oral bioavailability of curcumin in the blood up to 7 to 10 times that of curcumin 95%, based on published human trials
- A patented 100% natural turmeric extract (3 U.S. Patents awarded)
- Proprietary blend of curcuminoids and essential oil of turmeric
- Full spectrum of natural curcuminoids
- Extended retention of curcumin in the blood up to 8 to 12 hours
- Proven to support joint, immune, and brain function
- High ORAC value >13,000 per gram

Studies on BCM-95® Curcumin

Published Studies:

1. Human Clinical Study to evaluate the bioavailability of BCM-95 (Published: September 2006 Spice India pg 11-16)
3. Six-Month Randomized Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients with Alzheimer’s Disease (Published: Journal of Clinical Psychopharmacology, Vol 28, Number 1, Feb 2008 pg 110-114)
4. Curcumin effects on Blood Lipid profile in a 6-month human Study (Published: Elsevier Pharmacological Research 56(2007) pg 509-514.)
5. Oral Bioavailability of BCM-95 in Dogs. (Poster presentation. 2009 ACVIM Forum/Canadian VMA Convention: June 3-6, 2009; Montréal, Québec, Canada)

Unpublished Studies:

6. Toxicity study: BCM-95® curcumin does not cause toxicity even at 75 mg/110 gm weight dosed for 45 days.
7. BCM-95 Hepatoprotective (liver protective) Effect. Department of Biochemistry, University of Kerala.
Current Studies Under Peer Review for Publications:

8. Randomized, Controlled Human Clinical Study to Assess the efficacy and safety of BCM-95 & BosPure compared to Celecoxib in the management of Knee Osteoarthritis. Dose: 500 mg blend BCM-95 Curcumin and BosPure Bosellia twice daily vs 100 mg celecoxib (brand name Celebrex®) twice daily.
9. Randomized, Controlled Human Clinical Study to Assess the efficacy and safety of BCM-95 compared to Diclofenac Sodium (brand name Voltaren®) in the management of Active Rheumatoid Arthritis.
10. BCM-95 vs. fluoxetine (brand name Prozac®) for antidepressant effects.

Current-Ongoing Clinical Studies:

12. Martins R. Evaluation of the nutritional extract Bio-curcumin (BCM-95) to preserve cognitive functioning in a cohort of mild cognitively impaired (MCI) patients over 12 months. Edith Cowan University. Joondalup, Western Australia.
14. Pilot study: Comparison of 5 curcumin types in vitro: phosphatidylcholine (lecithin) bound curcumin in 4 to 1 ratio, BCM-95® curcumin, synthetic curcumin, bisdemethoxycurcumin, plain 95% curcumin. Baylor University, Texas.
15. BCM-95® curcumin impact on “sleeping gene” as partial mechanism of action for cancer prevention. Baylor University, Texas.
16. Effective curcumin on combination with anti-seizure drugs in reduced seizure activity and memory retention.